Lastly, it should be noted that the decision to screen and treat a man for prostate cancer, particularly a man aged 70 years or older, is an individual patient- and provider-level decision and that the assertions from our study cannot be blindly applied without thorough decision-making conversations regarding the pros and cons of PSA screening. The gene discussed is KLK3; the disease is Familial prostate cancer.